President Donald Trump signed an executive order imposing tariffs of up to 100% on certain patented drugs from companies that do not reach pricing agreements with his administration in the coming months [1]. Companies that have signed a 'most favored nation' pricing deal and are actively building facilities in the U.S. to onshore production of patented pharmaceuticals and their ingredients will be exempt from tariffs, while those building U.S. projects without a pricing deal will face a 20% tariff, which will increase to 100% in four years [1]. The administration has already secured 17 pricing deals with major drugmakers, 13 of which have signed, but did not specify which companies or drugs are at risk of the increased tariffs [1]. Larger companies have 120 days to negotiate before the tariffs take effect, while others have 180 days [1].
The executive order was issued on the anniversary of Trump's 'Liberation Day,' which previously saw sweeping import taxes that impacted global markets, though those tariffs were overturned by the Supreme Court in February [1]. The new pharmaceutical tariffs are justified by Trump as necessary to address national security concerns related to imports of pharmaceuticals and their ingredients [1].
Industry leaders have warned of negative consequences. Stephen J. Ubl, CEO of PhRMA, stated that taxes on cutting-edge medicines will increase costs and could jeopardize billions in U.S. investments, highlighting the existing robust U.S. biopharmaceutical manufacturing sector and noting that medicines sourced from abroad largely come from reliable U.S. allies [1].
The administration has used the threat of tariffs to negotiate deals with major companies such as Pfizer, Eli Lilly, and Bristol Myers Squibb, promising lower prices for new drugs [1]. Additionally, several countries have reached trade frameworks with the U.S. to cap tariffs on drugs: the EU, Japan, Korea, and Switzerland will face a 15% tariff, while the UK will see a 10% tariff, which is set to reduce to zero under future agreements [1].
CONCLUSION
Trump's executive order introduces significant tariffs on patented drugs, aiming to incentivize domestic production and lower prices. While some major companies have already reached pricing deals, industry leaders warn of increased costs and potential risks to U.S. investments. The move is expected to have a high market impact, especially for pharmaceutical companies and international trade partners.